PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
British Journal of Haematology10.1046/j.1365-2141.1998.1048.x19981021678-683Paclitaxel plus high-dose cyclosphosphamide with G-CSF support in patients with relapsed and refactory aggressive non-Hodgkin's lymphomahttp://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1046%2Fj.1365-2141.1998.1048.x, http://onlinelibrary.wiley.com/wol1/doi/10.1046/j.1365-2141.1998.1048.x/fullpdf
Cancer Treatment Reviews10.1016/s0305-7372(04)00120-32004306577-582Initial high dose chemotherapy plus autologous stem cell support improves survival outcomes compared with a standard CHOP regimen in people with higher intermediate risk aggressive lymphoma☆, ☆☆, ☆☆☆Abstracted from: Milpied N, Deconinck E, Gaillard F, et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 2004;350:1287–95.A GLASMACHERhttps://api.elsevier.com/content/article/PII:S0305737204001203?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0305737204001203?httpAccept=text/plain
Cancer Treatment Reviews10.1016/j.ctrv.2004.06.0042004306577-582Initial high dose chemotherapy plus autologous stem cell support improves survival outcomes compared with a standard CHOP regimen in people with higher intermediate risk aggressive lymphomaAxel Glasmacherhttps://api.elsevier.com/content/article/PII:S0305737204001203?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0305737204001203?httpAccept=text/plain
Clinical Lymphoma10.3816/clm.2000.n.018200013219-225CHOP Versus CHOP Plus ESHAP and High-Dose Therapy with Autologous Peripheral Blood Progenitor Cell Transplantation for High-Intermediate–Risk and High-Risk Aggressive Non-Hodgkin's LymphomaTanin Intragumtornchai, Wichai Prayoonwiwat, Tontanai Numbenjapon, Noppadol Assawametha, Rutchanee O'Charoen, Daratana Swasdikulhttps://api.elsevier.com/content/article/PII:S1526965511702299?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1526965511702299?httpAccept=text/plain
Clinical Lymphoma10.3816/clm.2004.s.00520045S22-S26Combining Yttrium 90–Labeled Ibritumomab Tiuxetan with High-Dose Chemotherapy and Stem Cell Support in Patients with Relapsed Non-Hodgkin's LymphomaJane N. Winterhttps://api.elsevier.com/content/article/PII:S1526965511701087?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1526965511701087?httpAccept=text/plain
European Journal of Haematology10.1034/j.1600-0609.2000.00250.x2000653188-194CyclOBEAP (cyclophosphamide, vincristine, bleomycin, etoposide, doxorubicin, prednisolone) regimen with granulocyte colony-stimulating factor (G-CSF) for patients with aggressive non-Hodgkin's lymphoma: a pilot studyNozomi Niitsu, Masataka Okamoto, Yasuaki Kuraishi, Shinobu Nakamura, Fumio Kodama, Masami Hiranohttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1034%2Fj.1600-0609.2000.00250.x, https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1034%2Fj.1600-0609.2000.00250.x, http://onlinelibrary.wiley.com/wol1/doi/10.1034/j.1600-0609.2000.00250.x/fullpdf
Internal Medicine Journal10.1111/j.1445-5994.2009.01795.x2009MODELING COST-EFFECTIVENESS OF HIGH DOSE CHEMOTHERAPY AS TREATMENT FOR RELAPSED AGGRESSIVE NON-HODGKIN'S LYMPHOMA IN AN AUSTRALIAN SETTINGJohanes Prajogo, Amanda Neil, Janine Duke, Hong Zhang, Barrie Stokes, Philip Rowlingshttp://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1445-5994.2009.01795.x
European Journal of Cancer Supplements10.1016/s1359-6349(05)81405-32005323201110 POSTER Early change of F-18 FDG uptake after chemotherapy in aggressive hodgkin's lymphoma and non-Hodgkin's lymphoma: the different pattern of F-18 FDG uptake between aggressive Hodgkin's lymphoma and non-Hodgkin's lymphomahttps://api.elsevier.com/content/article/PII:S1359634905814053?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1359634905814053?httpAccept=text/plain
British Journal of Haematology10.1046/j.1365-2141.1998.01048.x19981033678-683Paclitaxel plus high-dose cyclosphosphamide with G-CSF support in patients with relapsed and refractory aggressive non-Hodgkin's lymphomaAnas Younes, Jorge Romaguera, Ofelia Mesina, Frederick Hagemeister, Andreas H. Sarris, Maria A. Rodriguez, Peter Mclaughlin, Hector A. Preti, Carlos Bachier, Fernando Cabanillashttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1046%2Fj.1365-2141.1998.01048.x, https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1046%2Fj.1365-2141.1998.01048.x, http://onlinelibrary.wiley.com/wol1/doi/10.1046/j.1365-2141.1998.01048.x/fullpdf
Clinical Lymphoma10.1016/s1526-9655(11)70222-6200013218Commentary on “CHOP Chemotherapy with Preemptive Granulocyte Colony-Stimulating Factor in Elderly Patients with Aggressive Non-Hodgkin's Lymphoma: A Dose-Intensity Analysis”Thomas M. Habermannhttps://api.elsevier.com/content/article/PII:S1526965511702226?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1526965511702226?httpAccept=text/plain